ADAR1 Partners, LP's Form 4 filing
Palvella Therapeutics, Inc. (PVLA) · filed Aug 12, 2024
- Accession no.
- 0001940272-24-000006
- Filed
- Aug 12, 2024, 6:48 PM ET
- Trade date
- Aug 9-12, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $92.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| ADAR1 Partners, LPCIK 0001758866 | 10% Owner |
| ADAR1 Capital Management, LLCCIK 0001940272 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Common Stock | PPurchaseAcquired | +3,000 | $14.89 | +$44,678.7 | 127,331 | Indirect | |
| Aug 12, 2024 | Common Stock | PPurchaseAcquired | +2,243 | $15.88 | +$35,624.22 | 129,574 | Indirect | |
| Aug 12, 2024 | Common Stock | PPurchaseAcquired | +757 | $15.88 | +$12,022.98 | 15,067 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.